• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.

作者信息

Lebourgeois Samuel, Menidjel Reyene, Chenane Houssem Redha, Ferré Valentine Marie, Collin Gilles, Damond Florence, Coppée Romain, Yazdanpanah Yazdan, Timsit Jean-François, Houhou-Fidouh Nadhira, Descamps Diane, Charpentier Charlotte, Visseaux Benoit

机构信息

Service de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France.

Service de Virologie, Hôpital Bichat Claude Bernard, Université de Paris, IAME, INSERM, 46, rue Henri Huchard, Paris F-75018, France.

出版信息

J Infect. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.11.012. Epub 2021 Nov 19.

DOI:10.1016/j.jinf.2021.11.012
PMID:34808243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8603409/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a4b/8603409/5c4bff127580/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a4b/8603409/40e4ca54b927/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a4b/8603409/5c4bff127580/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a4b/8603409/40e4ca54b927/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a4b/8603409/5c4bff127580/gr2_lrg.jpg

相似文献

1
Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.阿尔法（B.1.1.7）和德尔塔（B.1.617.2 - AY.40）新冠病毒变异株在接种疫苗后M4时呈现出强烈的中和作用衰减，且复制速度比D614G（B.1）谱系更快。
J Infect. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.11.012. Epub 2021 Nov 19.
2
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.辉瑞-BioNTech 新冠疫苗接种 6 个月后针对 SARS-CoV-2 关注变异株的抗体反应
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.
3
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.mRNA-1273 对 SARS-CoV-2 变异株的血清中和活性。
J Virol. 2021 Nov 9;95(23):e0131321. doi: 10.1128/JVI.01313-21. Epub 2021 Sep 22.
4
Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.BNT162b2疫苗诱导产生的针对真实B.1、B.1.1.7、B.1.351、B.1.525和P.1型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的中和抗体血清学调查
Emerg Microbes Infect. 2021 Dec;10(1):1241-1243. doi: 10.1080/22221751.2021.1940305.
5
Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.CoronaVac 疫苗诱导的抗体对 alpha、gamma 和 D614G SARS-CoV-2 变异株的中和作用。
J Med Virol. 2022 Jan;94(1):399-403. doi: 10.1002/jmv.27310. Epub 2021 Sep 8.
6
Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.根据 BNT162b2 疫苗接种和感染史，抗 SARS-CoV-2 免疫球蛋白同种型和对病毒变异体的中和活性。
Front Immunol. 2021 Dec 17;12:793191. doi: 10.3389/fimmu.2021.793191. eCollection 2021.
7
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
8
Evaluation of Neutralizing Antibodies against SARS-CoV-2 Variants after Infection and Vaccination Using a Multiplexed Surrogate Virus Neutralization Test.评估感染和接种疫苗后针对 SARS-CoV-2 变异体的中和抗体：使用多重假病毒中和试验。
Clin Chem. 2022 May 18;68(5):702-712. doi: 10.1093/clinchem/hvab283.
9
In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.体外中和活性的 BNT162b2 mRNA 诱导的抗体对完整的 B.1.351 SARS-CoV-2 变体。
Transbound Emerg Dis. 2022 Sep;69(5):2649-2655. doi: 10.1111/tbed.14417. Epub 2022 Jan 3.
10
Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.BNT162b2 和 mRNA-1273 疫苗诱导的针对严重急性呼吸综合征冠状病毒-2 变异株的中和抗体效力：体外研究的系统评价。
Rev Med Virol. 2022 Mar;32(2):e2277. doi: 10.1002/rmv.2277. Epub 2021 Jul 19.

引用本文的文献

1
Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response.胸腺基质淋巴细胞生成素通过诱导树突状细胞依赖性生发中心反应来提高新冠病毒亚单位疫苗的保护性免疫。
J Virol. 2025 Apr 15;99(4):e0232324. doi: 10.1128/jvi.02323-24. Epub 2025 Mar 4.
2
Differential activation of human neutrophils by SARS-CoV-2 variants of concern.SARS-CoV-2 关切变异株对人中性粒细胞的差异化激活。
Front Immunol. 2022 Oct 27;13:1010140. doi: 10.3389/fimmu.2022.1010140. eCollection 2022.
3
A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants.

本文引用的文献

1
Waning Immunity after the BNT162b2 Vaccine in Israel.以色列接种 BNT162b2 疫苗后的免疫力下降。
N Engl J Med. 2021 Dec 9;385(24):e85. doi: 10.1056/NEJMoa2114228. Epub 2021 Oct 27.
2
Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.在接种两剂BNT162b2疫苗后的4个月内，医护人员的体液免疫反应有所下降。
J Infect. 2022 Feb;84(2):248-288. doi: 10.1016/j.jinf.2021.09.017. Epub 2021 Sep 29.
3
Antibody titers and protection against a SARS-CoV-2 infection.抗体滴度与对SARS-CoV-2感染的防护作用
一株表达 ACE2 和 TMPRSS2 的新型工程化 A549 细胞系对 SARS-CoV-2，包括德尔塔和奥密克戎变异株高度易感。
Viruses. 2022 Jun 23;14(7):1369. doi: 10.3390/v14071369.
4
Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.使用中和及特异性酶联免疫吸附测定法检测疫苗抗体对奥密克戎和新冠病毒变体的中和作用。
J Infect. 2022 Jun;84(6):834-872. doi: 10.1016/j.jinf.2022.02.031. Epub 2022 Mar 10.
J Infect. 2022 Feb;84(2):248-288. doi: 10.1016/j.jinf.2021.09.013. Epub 2021 Sep 21.
4
The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients.在新诊断的新冠患者的鼻咽样本中，新冠病毒德尔塔变异株的病毒载量高于贝塔变异株和既往变异株。
J Infect. 2021 Oct;83(4):e1-e3. doi: 10.1016/j.jinf.2021.08.027. Epub 2021 Aug 19.
5
Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ.新型冠状病毒肺炎疫苗接种后特异性抗体下降——确定血清阳性率和血清中和的阈值不同。
J Infect. 2021 Oct;83(4):e4-e5. doi: 10.1016/j.jinf.2021.08.023. Epub 2021 Aug 15.
6
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
7
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.传染性 SARS-CoV-2 B.1.1.7 和 B.1.351 变体对中和抗体的敏感性。
Nat Med. 2021 May;27(5):917-924. doi: 10.1038/s41591-021-01318-5. Epub 2021 Mar 26.
8
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.SARS-CoV-2 变体 B.1.351 从自然和疫苗诱导的血清中逃逸的证据。
Cell. 2021 Apr 29;184(9):2348-2361.e6. doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23.
9
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.社区检出的 SARS-CoV-2 谱系 B.1.1.7 病例死亡率增加。
Nature. 2021 May;593(7858):270-274. doi: 10.1038/s41586-021-03426-1. Epub 2021 Mar 15.
10
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study.202012/1 感染关注的 SARS-CoV-2 变异株的患者的死亡率风险：匹配队列研究。
BMJ. 2021 Mar 9;372:n579. doi: 10.1136/bmj.n579.